Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price

Amgen EVP Murdo Gordon highlighted the unmet need for women at high risk, including those with a prior fracture. At $1,825 per month or $21,900 for a one-year course in the US, he says Evenity's cost is much lower versus competing 18- and 24-month anabolic agents.

Launches Pricing Strategies

AstraZeneca's Imfinzi Cements Market Position In Lung Cancer Segment With UK NICE Okay

But because of the remaining uncertainty in the clinical evidence for this "potentially curative treatment," – Imfinzi for Stage III NSCLC – UK reimbursement will come from the Cancer Drugs Fund until more data accrues from the PACIFIC study, due to report in 2021.

 

Health Technology Assessment ImmunoOncology

How One Startup Plans To Win Primary Care Battle In China

Millions of people lack access to quality healthcare services and products in China, but now one company has raised millions in funding and vows to harness the power of the internet to get temperature-controlled drugs and quality diagnostic services to everyone who needs them.

Digital Health Commercial

Zulresso Is Sage’s First Step In Postpartum Depression Treatment

I.V. Zulresso is the first US FDA-approved drug for postpartum depression (PPD) and Sage's first commercial product – with a list price of $34,000. It will help the company build a presence in PPD as it completes late-stage development for oral candidate SAGE-217.

Approvals Launches

Cancer, Rare Disease Drugs To Be Covered As China Expands Reimbursement

China's national reimbursement drug list will undergo a much anticipated expansion in 2019, and therapies for cancer, pediatric and rare conditions from international firms including Roche and Actellion are likely to receive long-awaited coverage.

China Market Access

Ortho Derm Turns To Cash-Pay Model To Address Prior Authorization Hurdles

With dermatologists reporting issues with prior authorization requirements, Ortho Derm is offering several reduced-price products under a new cash-pay format.

Pricing Strategies Dermatology

Vertex CEO Defends Salary After Company Is Slammed For Orkambi Pricing At UK Hearing

Vertex CEO Jeff Leiden has defended his company’s approach to pricing, as well as his $17m salary, at a heated UK public hearing on access to cystic fibrosis drug Orkambi.

Europe United Kingdom

ICER's Review Of Rebate Reform, At A Glance

The Institute for Clinical and Economic Review has weighed in on the pros and cons of rebate reform, surveying an assortment of payers, pharmacy benefit managers and pharmaceutical companies on alternative rebate models and their potential impact. 

Pharmacy Benefit Management Pricing Debate

Dialling Back On China Amid Trade War? Not So Fast

Healthcare is among the few sectors that is still optimistic about China's market growth amid a slowing economy, driven by closer integration with ever-strong global demand, but the ongoing US trade war and rising protections present new challenges, says a major US trade group in China.

China Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register